Skip to main content

Advertisement

Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

Article metrics

  • 882 Accesses

The original article was published in Journal of Hematology & Oncology 2017 10:153

Correction

The original article [1] contains two errors in Table 2:

  1. 1)

    The data values in the rows ‘Disease control rate’ and ‘Objective response rate’ and the columns ‘With adverse events’ and ‘Without adverse events’ have mistakenly been interchanged between columns; the values ‘39 (32.77)’ and ‘6 (5.04)’ should be swapped with the values ‘82 (54.67)’ and ‘11 (7.33)’ respectively.

  2. 2)

    The value for the row ‘Median progression-free survival (IQR)’ for the ‘HR/OR’ sub-column should be 0.69, not 0.79.

Table 2 Correlation between presence of at least one anti-angiogenesis-related adverse event and antitumor efficacy of apatinib

As such, the table displayed ahead shows the correct presentation of Table 2 and should be considered instead.

Reference

  1. 1.

    Liu X, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017;10:153.

Download references

Author information

Correspondence to Pagona Lagiou or Jin Li.

Additional information

The original article can be found online at https://doi.org/10.1186/s13045-017-0521-0.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark